Pfizer’s Lyme Gambit Clears European Regulators, But the Market Yawns
(SeaPRwire) – By: Oliver Hawthorne
European regulators just moved a step closer to greenlighting the first human defense against a pervasive outdoor hazard, yet Wall Street and European bourses barely blinked. The silence from the trading floor stands in sharp contrast to the sheer scale of the medical barrier Pfizer and its partner Valneva are attempting to scale across the continent.
The European Medicines Agency has officially validated the Marketing Authorization Application for PF-07307405, setting off a formal scientific evaluation of the experimental jab. This regulatory milestone follows data from the Phase 3 VALOR study, which tracked participants aged five years and older in regions where outdoor exposure poses a daily risk. The candidate targets outer surface protein A, or OspA, on Borrelia bacteria, prompting the human body to generate antibodies against six common serotypes to block transmission when infected ticks feed.
Lyme disease remains the primary vector-borne infection in Europe, touching more than 100,000 people every year while over 200 million residents live in high-risk zones. Untreated cases cascade into severe joint, skin, nervous system, and cardiac complications. Despite this massive disease burden and the absence of any currently approved human vaccine in either Europe or North America, Pfizer stock hovered flat at $26.78 following the announcement, showing that institutional investors demand actual commercial revenue over regulatory paperwork.
Pfizer and Valneva have been building this pipeline since their initial collaboration agreement in April 2020, with Pfizer holding exclusive manufacturing and commercialization rights. If the full scientific review clears, PF-07307405 will finally transition from clinical ambition to a commercial asset, opening up an entirely untapped vaccine category for Pfizer’s late-stage portfolio. The real test of value, however, will not happen inside the EMA review rooms, but at the pharmacy counter once the commercial rollout begins.
Author bio: Oliver Hawthorne, a Principal Correspondent permanently stationed at an international technology review, focusing on the intersection of biotech regulatory milestones and enterprise market valuations.